Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-8-10
pubmed:abstractText
The capacity of interferon beta to alter the course of multiple sclerosis has promoted a new therapeutic concept, based upon the modulation of the immune response rather than its suppression. As the proteasome plays a crucial role in the control of the inflammatory process and immune cell survival, targeting the proteasome appears as a novel approach for the prevention and treatment of inflammatory autoimmune diseases. We have previously shown that ritonavir, an HIV-1 protease inhibitor used in AIDS therapy, can modulate the proteasome function by inhibiting the chymotrypsin-like activity and enhancing the trypsin-like activity. We have, therefore, explored its therapeutic potential on experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis, in Lewis rats and SJL mice. Daily administration of ritonavir during autoimmune antigen stimulation prevented clinical symptoms of EAE in a dose- and time-dependent manner. This protection was accompanied by an inhibition of the mononuclear cell infiltration into the central nervous system usually observed in EAE. Despite a complete absence of clinical symptoms during first EAE induction, ritonavir-treated animals became resistant to further induction of EAE, suggesting an immune mechanism of protection. These results suggest that proteasome modulation using ritonavir or analogues may be of interest for patients with multiple sclerosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0165-5728
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
118
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
233-44
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11498258-Animals, pubmed-meshheading:11498258-Cell Movement, pubmed-meshheading:11498258-Cysteine Endopeptidases, pubmed-meshheading:11498258-Disease Models, Animal, pubmed-meshheading:11498258-Dose-Response Relationship, Drug, pubmed-meshheading:11498258-Drug Administration Schedule, pubmed-meshheading:11498258-Drug Therapy, Combination, pubmed-meshheading:11498258-Encephalomyelitis, Autoimmune, Experimental, pubmed-meshheading:11498258-Female, pubmed-meshheading:11498258-HIV Protease Inhibitors, pubmed-meshheading:11498258-Leukocytes, Mononuclear, pubmed-meshheading:11498258-Mice, pubmed-meshheading:11498258-Mice, Inbred Strains, pubmed-meshheading:11498258-Multienzyme Complexes, pubmed-meshheading:11498258-Myelin Basic Proteins, pubmed-meshheading:11498258-Proteasome Endopeptidase Complex, pubmed-meshheading:11498258-Rats, pubmed-meshheading:11498258-Rats, Inbred Lew, pubmed-meshheading:11498258-Ritonavir, pubmed-meshheading:11498258-Saquinavir, pubmed-meshheading:11498258-Spinal Cord
pubmed:year
2001
pubmed:articleTitle
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.
pubmed:affiliation
INSERM U421, Faculté de Médecine 8, rue du général Sarrail, 94010 cedex, Créteil, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't